| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IRF9 |
| Uniprot No | Q00978 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-393aa |
| 氨基酸序列 | MASGRARCTRKLRNWVVEQVESGQFPGVCWDDTAKTMFRIPWKHAGKQDFREDQDAAFFKAWAIFKGKYKEGDTGGPAVWKTRLRCALNKSSEFKEVPERGRMDVAEPYKVYQLLPPGIVSGQPGTQKVPSKRQHSSVSSERKEEEDAMQNCTLSPSVLQDSLNNEEEGASGGAVHSDIGSSSSSSSPEPQEVTDTTEAPFQGDQRSLEFLLPPEPDYSLLLTFIYNGRVVGEAQVQSLDCRLVAEPSGSESSMEQVLFPKPGPLEPTQRLLSQLERGILVASNPRGLFVQRLCPIPISWNAPQAPPGPGPHLLPSNECVELFRTAYFCRDLVRYFQGLGPPPKFQVTLNFWEESHGSSHTPQNLITVKMEQAFARYLLEQTPEQQAAILSLV |
| 预测分子量 | 43,6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IRF9重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*"Recombinant IRF9 enhances interferon signaling in hepatic cells and inhibits hepatitis B virus replication"*
**作者**：Li, Y., et al.
**摘要**：该研究利用大肠杆菌系统成功表达并纯化重组人IRF9蛋白，证明其与STAT1/STAT2形成复合物后可显著增强干扰素α诱导的抗病毒反应，并在体外模型中有效抑制乙肝病毒复制，提示其在抗病毒治疗中的潜在应用。
2. **文献名称**：*"Structural basis of IRF9-DNA binding and its role in type I interferon signaling"*
**作者**：Chen, X., et al.
**摘要**：通过昆虫细胞表达系统获得高纯度IRF9重组蛋白，结合X射线晶体学分析其DNA结合域结构。研究发现IRF9通过特定氨基酸残基与干扰素刺激反应元件(ISRE)结合，并阐明了其在I型干扰素通路中调控基因表达的分子机制。
3. **文献名称**：*"Functional characterization of IRF9 phosphorylation sites using recombinant protein mutagenesis"*
**作者**：Wang, T., et al.
**摘要**：研究团队通过哺乳动物细胞表达系统制备了不同磷酸化位点突变的IRF9重组蛋白，发现丝氨酸残基(S206)的磷酸化是IRF9核转位及与STAT1/STAT2复合物稳定性的关键因素，揭示了翻译后修饰对其功能的调控作用。
(注：上述文献信息为示例性内容，实际引用时请核实具体文献的准确性。)
The IRF9 (Interferon Regulatory Factor 9) recombinant protein is a genetically engineered form of the naturally occurring transcription factor that plays a pivotal role in interferon (IFN)-mediated immune responses. IRF9 is a member of the interferon regulatory factor family, which regulates the expression of IFN-stimulated genes (ISGs) critical for antiviral defense, immune modulation, and cell cycle regulation. It functions as a key component of the IFN signaling cascade, particularly in the JAK-STAT pathway. Upon IFN stimulation, IRF9 forms a complex with phosphorylated STAT1 and STAT2. known as the IFN-stimulated gene factor 3 (ISGF3). This trimeric complex translocates to the nucleus, binds to IFN-stimulated response elements (ISREs) in target gene promoters, and initiates transcription of ISGs to mount antiviral and antiproliferative responses.
Recombinant IRF9 is typically produced using expression systems such as *E. coli*, mammalian cells, or insect cells, followed by purification via affinity tags (e.g., His-tag). Its production enables detailed biochemical and functional studies, including investigations into IFN signaling dysregulation in diseases like cancer, autoimmune disorders, and chronic viral infections. Researchers use recombinant IRF9 to explore its structural interactions within the ISGF3 complex, its role in modulating immune responses, and its potential as a therapeutic target or tool for enhancing IFN-based therapies. Additionally, it serves as a reagent in drug screening assays to identify compounds that modulate IFN pathways. The availability of recombinant IRF9 has significantly advanced understanding of innate immunity and IFN-dependent mechanisms, offering insights into novel treatment strategies for immune-related pathologies.
×
